"The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus.
Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim (trimethoprim (trimethoprim tablet) tablet) . Therapy may be initiated prior to obtaining the results of these tests.
DOSAGE AND ADMINISTRATION
The usual oral adult dosage is 100 mg of trimethoprim every 12 hours or 200 mg trimethoprim (trimethoprim (trimethoprim tablet) tablet) (two 100 mg tablets) every 24 hours, each for 10 days. The use of trimethoprim (trimethoprim (trimethoprim tablet) tablet) in patients with a creatinine clearance of less than 15 mL/min is not recommended.
For patients with a creatinine clearance of 15 to 30 mL/min, the dose should be 50 mg every 12 hours.
Trimethoprim (trimethoprim (trimethoprim tablet) tablet) Tablets USP, 100 mg are scored, oval-shaped, white tablets imprinted DAN DAN and 5571 supplied in bottles of 100.
Dispense in a tight, light-resistant container with child-resistant closure.
Store at 20°-25°C (68°-77°F) in a dry place. [See USP controlled room temperature.]
Watson Laboratories, Inc., Corona, CA 92880, USA. Revised: June 2006. FDA rev date: 5/1/2002This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 9/18/2008
Additional Trimethoprim Information
Report Problems to the Food and Drug Administration
Find out what women really need.